Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 3/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.31 |
| ▸ | BHMT | Q93088 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13585419 | 0.86 | DDAH1 (0.38) | DDAH1PMP22LIPGGSTO1NOS3 | |
| SCHEMBL1769337 | 0.83 | PMP22 (0.35) | GFPT1CASRPMP22NOS3NOS1 | |
| SCHEMBL13584917 | 0.81 | NOS2 (0.36) | GFPT1CASRPMP22NOS3NOS1 | |
| SCHEMBL13585238 | 0.77 | PMP22 (0.40) | GFPT1CASRPMP22NOS3NOS1 | |
| SCHEMBL13585241 | 0.77 | PMP22 (0.40) | GFPT1CASRPMP22NOS3NOS1 | |
| SCHEMBL13585153 | 0.77 | DDAH1 (0.36) | DDAH1PMP22LIPGGSTO1NOS3 | |
| SCHEMBL13585156 | 0.77 | DDAH1 (0.36) | DDAH1PMP22LIPGGSTO1NOS3 | |
| SCHEMBL13585040 | 0.76 | PMP22 (0.45) | DDAH1PMP22NOS3NOS1NOS2 | |
| SCHEMBL13585042 | 0.76 | PMP22 (0.45) | DDAH1PMP22NOS3NOS1NOS2 | |
| SCHEMBL1769603 | 0.74 | CA12 (0.44) | GFPT1DDAH1CASRPMP22SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | GFPT1 3069/4885DDAH1 3491/4885CASR 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.